Skip to main content
IBRX
NASDAQ Life Sciences

ANKTIVA Plus BCG Hits Primary Endpoint in BCG-Naïve Bladder Cancer Trial

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$8.76
Mkt Cap
$9.152B
52W Low
$1.95
52W High
$12.43
52W Position info
349% above low
Off High info
30% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

IBRX has more than doubled off its 52-week low of $1.95.

Summary

The randomized, controlled QUILT-2.005 trial met its primary endpoint: adding intravesical ANKTIVA to BCG produced a statistically significant efficacy improvement over BCG alone in BCG-naïve, high-grade NMIBC patients with carcinoma in situ, with or without papillary tumors. Safety was consistent with BCG alone and no treatment-related deaths were reported. This is the frontline setting — roughly 40 years of BCG-only standard of care — and it is a much larger patient population than the BCG-unresponsive label ANKTIVA already holds. Database lock occurred October 20, 2026, and the company says the supplemental BLA is on track for submission before year-end 2026. That filing is the next hard milestone; approval would extend ANKTIVA earlier in the disease course and broaden the addressable market. The stock is up sharply on the readout, and the binary risk now shifts to FDA acceptance and review of the sBLA.

At the time of this announcement, IBRX was trading at $8.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2B. The 52-week trading range was $1.95 to $12.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

IBRX - Latest Insights

IBRX
Nov 09, 2026, 7:52 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.59
Real-time Price: $6.64 info
Change: -$0.9474 (-12%) info
Market Cap: $7.096B info
IBRX
Nov 09, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.09
Real-time Price: $6.64 info
Change: -$1.45 (-18%) info
Market Cap: $7.096B info
IBRX
Nov 09, 2026, 7:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.84
Real-time Price: $6.64 info
Change: -$2.20 (-25%) info
Market Cap: $7.096B info
IBRX
Oct 16, 2026, 11:49 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.42
Real-time Price: $6.64 info
Change: -$2.78 (-29%) info
Market Cap: $7.096B info
IBRX
Oct 14, 2026, 11:31 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $9.74
Real-time Price: $6.64 info
Change: -$3.10 (-32%) info
Market Cap: $7.096B info